About this trial

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion. It is also important for the regulation of cell growth of the gastric mucosal.

In a healthy person, progastrin is not detectable in the peripheral blood. However, progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, cervix uterus, melanoma…) The gene GAST coding for progastrin is a direct target gene of the WNT/ß-catenin oncogenic pathway. The activation of this oncogenic pathway is an early event in cancer development.

Chronic activation of the WNT/ß-catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation.

Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for diagnosis and prognosis at different stages.

Eligibility criteria

Qualifiers

Head and neck carcinomas

Thyroid cancer

Pancreatic carcinomas

Ovarian adenocarcinomas

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Blood draws

Treatment groups

410 Participants
are divided into 1 treatment group

Locations

17
Service de NEURO-ONCOLOGIE du Groupement Hospitalier EST Bron France
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'hôpital de la Croix-Rousse Lyon France
Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'Hôpital E. Herriot Lyon France
Service d'Oto-Rhino-Laryngologie de l'Hôpital de la Croix-Rousse Lyon France

Sponsors and collaborators

Hospices Civils de Lyon

Lead sponsor